| |
| |
|
| Insider
Information: |
Labrucherie Gil M |
| Relationship: |
Chief Financial Officer |
| City: |
San Carlos |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
319,155 |
|
|
Indirect Shares
|
94,335 |
|
|
| Direct
Value |
$406,488 |
|
|
|
Indirect Value
|
$483,425 |
|
|
| Total
Shares |
413,490 |
|
|
| Total
Value |
$889,913 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
6
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
6
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-6.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -181.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Nektar Therapeutics |
NKTR |
SVP, COO & CFO |
2022-05-16 |
312,905 |
2008-11-14 |
0 |
Premium* |
|
|
Rezolute, Inc |
RZLT |
Director |
2022-05-04 |
0 |
2022-05-04 |
53,572 |
Premium* |
|
|
Acelyrin, Inc. |
SLRN |
Chief Financial Officer |
2023-10-04 |
6,250 |
2023-10-04 |
40,763 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2008-11-14 |
4 |
S |
$4.37 |
$1,752 |
D/D |
(401) |
1,968 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2009-05-12 |
4 |
S |
$5.57 |
$2,200 |
D/D |
(395) |
2,662 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2016-02-17 |
4 |
S |
$11.92 |
$9,858 |
D/D |
(827) |
6,590 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2016-05-17 |
4 |
S |
$13.58 |
$11,353 |
D/D |
(836) |
7,921 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2016-08-16 |
4 |
S |
$17.56 |
$58,036 |
D/D |
(3,305) |
52,783 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2016-11-16 |
4 |
S |
$13.96 |
$23,090 |
D/D |
(1,654) |
51,129 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2017-02-16 |
4 |
S |
$13.14 |
$30,997 |
D/D |
(2,359) |
69,270 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2017-05-16 |
4 |
S |
$19.55 |
$62,149 |
D/D |
(3,179) |
66,091 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2017-08-16 |
4 |
S |
$19.32 |
$61,380 |
D/D |
(3,177) |
63,414 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2018-02-16 |
4 |
S |
$82.94 |
$288,382 |
D/D |
(3,477) |
99,739 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2018-05-16 |
4 |
S |
$83.39 |
$412,030 |
D/D |
(4,941) |
94,798 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2018-11-16 |
4 |
S |
$38.25 |
$249,199 |
D/D |
(6,515) |
106,544 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2019-02-19 |
4 |
S |
$42.39 |
$152,265 |
D/D |
(3,592) |
131,702 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2019-05-16 |
4 |
S |
$31.37 |
$118,171 |
D/D |
(3,767) |
127,935 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
• – – |
2019-08-16 |
4 |
S |
$18.15 |
$91,893 |
D/D |
(5,063) |
122,872 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2019-11-18 |
4 |
S |
$17.97 |
$159,268 |
D/D |
(8,863) |
219,009 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2020-02-18 |
4 |
S |
$22.35 |
$132,714 |
D/D |
(5,938) |
253,221 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2020-11-16 |
4 |
S |
$16.93 |
$140,113 |
D/D |
(8,276) |
226,973 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-02-16 |
4 |
S |
$22.37 |
$178,445 |
D/D |
(7,977) |
258,996 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2021-05-17 |
4 |
S |
$18.30 |
$144,533 |
D/D |
(7,898) |
251,098 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2022-02-16 |
4 |
S |
$10.95 |
$82,990 |
D/D |
(7,579) |
301,603 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
• – – |
2022-05-16 |
4 |
S |
$3.95 |
$68,920 |
D/D |
(17,448) |
312,905 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2008-11-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,122 |
2,369 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2009-05-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,089 |
3,057 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
SVP & General Counsel |
• – – |
2011-03-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,089 |
3,057 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
